CO2023016217A2 - Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos - Google Patents

Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos

Info

Publication number
CO2023016217A2
CO2023016217A2 CONC2023/0016217A CO2023016217A CO2023016217A2 CO 2023016217 A2 CO2023016217 A2 CO 2023016217A2 CO 2023016217 A CO2023016217 A CO 2023016217A CO 2023016217 A2 CO2023016217 A2 CO 2023016217A2
Authority
CO
Colombia
Prior art keywords
pyrrolo
substituted phenyl
pyridine derivatives
protein
useful
Prior art date
Application number
CONC2023/0016217A
Other languages
English (en)
Inventor
Samuël Dominique Demin
Vineet Pande
Wim Bert Griet Schepens
Wei Cai
Xuedong Dai
Olivier Alexis Georges Querolle
Ming Li
Xiangjun Deng
Alicia Tee Fuay Ng
Johannes Wilhelmus J Thuring
Fabian Hulpia
Chao Liang
Zhen Sun
Zhigao Zhang
Natalia Nikolaevna Dyubankova
Matthieu Dominique Jouffroy
Susan Lepri
Nicolas Freddy Jacques Bruno Darville
James Patrick Edwards
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2023016217A2 publication Critical patent/CO2023016217A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero, con la composición farmacéutica que comprende tales compuestos y su uso como inhibidores de la interacción entre menina/proteína MLL/proteína, útiles para tratar enfermedades tales como el cáncer, que incluye, sin limitarse a, la leucemia, síndrome mielodisplásico (SMD) y las neoplasias mieloproliferativas (NMP); y la diabetes.
CONC2023/0016217A 2021-06-01 2023-11-29 Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos CO2023016217A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021097679 2021-06-01
CN2022085680 2022-04-08
PCT/CN2022/095901 WO2022253167A1 (en) 2021-06-01 2022-05-30 SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
CO2023016217A2 true CO2023016217A2 (es) 2023-12-11

Family

ID=82016507

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0016217A CO2023016217A2 (es) 2021-06-01 2023-11-29 Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos

Country Status (16)

Country Link
US (1) US20230250096A1 (es)
EP (1) EP4347588A1 (es)
JP (1) JP2024521879A (es)
KR (1) KR20240016324A (es)
CN (1) CN117396476A (es)
AR (1) AR126011A1 (es)
AU (1) AU2022286467A1 (es)
CA (1) CA3218479A1 (es)
CO (1) CO2023016217A2 (es)
DO (1) DOP2023000250A (es)
EC (1) ECSP23095641A (es)
IL (1) IL308862A (es)
MX (1) MX2023014347A (es)
TW (1) TW202313606A (es)
UY (1) UY39795A (es)
WO (1) WO2022253167A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023193790A1 (en) 2022-04-08 2023-10-12 Janssen Pharmaceutica Nv Crystalline forms of an inhibitor of the menin/mll interaction
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
WO2024114664A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473054B1 (en) 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
WO2011056440A1 (en) 2009-10-27 2011-05-12 Boehringer Ingelheim International Gmbh Heterocyclic compounds as ccr1 receptor antagonists
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
SG11201400277VA (en) 2011-09-14 2014-05-29 Proximagen Ltd New enzyme inhibitor compounds
EP2968342B1 (en) 2013-03-13 2018-10-03 The Regents of the University of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
EP3302057A4 (en) 2015-06-04 2018-11-21 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
MX2018007703A (es) 2015-12-22 2018-11-09 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-linaje leucemico mixto.
CA3012649A1 (en) 2016-01-26 2017-08-03 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in npm1 mutant leukemia
AU2017235462B2 (en) 2016-03-16 2021-07-01 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
ES2947636T3 (es) 2016-03-16 2023-08-14 Kura Oncology Inc Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso
CA3022868A1 (en) 2016-05-02 2017-11-09 Shaomeng Wang Piperidines as menin inhibitors
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
KR102436430B1 (ko) 2016-06-10 2022-08-24 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
DK3512850T3 (da) 2016-09-16 2023-07-03 Vitae Pharmaceuticals Llc Inhibitorer af menin-mll-interaktionen
EA201990699A1 (ru) 2016-10-05 2019-09-30 Янссен Фармацевтика Нв Спиробициклические ингибиторы взаимодействия менин–mll
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE
EP3856173A4 (en) 2018-09-26 2022-07-06 Kura Oncology, Inc. TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS
WO2021060453A1 (ja) 2019-09-27 2021-04-01 大日本住友製薬株式会社 架橋型光学活性２級アミン誘導体
WO2021121327A1 (en) 2019-12-19 2021-06-24 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Also Published As

Publication number Publication date
MX2023014347A (es) 2023-12-13
EP4347588A1 (en) 2024-04-10
TW202313606A (zh) 2023-04-01
US20230250096A1 (en) 2023-08-10
DOP2023000250A (es) 2024-04-30
JP2024521879A (ja) 2024-06-04
KR20240016324A (ko) 2024-02-06
CA3218479A1 (en) 2022-12-08
AU2022286467A1 (en) 2024-01-25
IL308862A (en) 2024-01-01
WO2022253167A1 (en) 2022-12-08
WO2022253167A8 (en) 2023-03-09
CN117396476A (zh) 2024-01-12
ECSP23095641A (es) 2024-01-31
UY39795A (es) 2022-11-30
AR126011A1 (es) 2023-08-30

Similar Documents

Publication Publication Date Title
CL2022001583A1 (es) Derivados espiráncos sustituidos de cadena lineal
ECSP23095641A (es) Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos
CL2018003577A1 (es) Piridina substituida como inhibidor de dnmt1.
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
GT200600398A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
ECSP066928A (es) Derivados de carbolina útiles en la inhibición de la angiogénesis
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
UY35293A (es) Isotiazoles sustituidos con amino
CR10056A (es) [(1h-indol-5-il)-heteroariloxi]-(1-aza-biciclo[3.3.1]nonanos como ligandos colinérgicos del n-achr para el tratamiento de trastornos piscóticos y neurodegenerativos
UY29325A1 (es) Nuevos derivados de 2 - amino-piridina
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
CL2021001308A1 (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteína de los mismos para su uso como agonistas de lxr.
ECSP088472A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
MX2023013176A (es) Derivados espiro sustituidos.
MX2023013174A (es) Derivados espiro sustituidos.
CL2016000024A1 (es) Volasertib en combinación con decitabina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico.
BR112019012106A2 (pt) inibidores de azepano de interação menin-mill
BR112023025436A2 (pt) Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
CO2023018577A2 (es) Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer
ECSP23019518A (es) Derivados de tetrahidroisoquinolina para el tratamiento de eritrocitos y enfermedades inflamatorias
UY39865A (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer
AR046099A1 (es) Mezclas fungicidas para combatir patogenos del arroz conteniendo derivados de tiazolopirimidina y fluazinam
AR044807A1 (es) Derivados de triazolopirimidina y bencimidazol (benomil) y su uso en una mezcla fungicida
AR044808A1 (es) Derivados de triazolopirimidina y pirimidianilidas y su uso en una mezcla fungicida